Aurobindo Pharma Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 12,95,816 shares,. Its Average Traded Price (ATP) is ₹1790.82, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 27 @ ₹1800.00.
Aurobindo Pharma has an upper circuit limit of ₹1963.50 and a lower circuit limit of ₹1606.50. The total value traded stands at ₹232.06 CR, and the delivery percentage for the day is 34.68%.
The stock is currently traded with a market lot size of 1. Aurobindo Pharma also offers a dividend yield of 0.22%.
Aurobindo Pharma Share Price Chart
Aurobindo Pharma Share Key Metrics
Volume
12.96 L
Market Cap
103568.02 CR
LTQ@LTP
27@1800.00
ATP
1790.82
Var Margin
14.26 %
Circuit Range
1606.5-1963.5
Delivery %
34.68 %
Value
232.06 CR
ASM/GSM
No
Market Lot
1
Aurobindo Pharma Resistance and Support
Pivot 1759.27
Resistance
First Resistance
1822.54
Second Resistance
1860.07
Third Resistance
1923.34
Support
First Support
1721.74
Second Support
1658.47
Third Support
1620.94
Aurobindo Pharma Futures & Options
1800
15 (0.84%)
Aurobindo Pharma Option Chain
View Price, OI, Greeks & More...
23NOV26
1790.40
10.60 (0.60%)
29DEC26
1798.90
10.50 (0.59%)
25JAN27
1810.00
10.60 (0.59%)
AUROPHARMA|23NOV26 CE 1780.00
42.40
5.35 (14.44%)
AUROPHARMA|23NOV26 PE 1800.00
43
-6.4 (-12.96%)
Aurobindo Pharma Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Aurobindo Pharma Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-04 | Quarterly Results & Interim Dividend |
| 2026-08-05 | Quarterly Results |
| 2026-05-21 | Audited Results |
| 2026-04-06 | Buy Back of Shares |
| 2026-02-09 | Quarterly Results |
| 2025-11-05 | Quarterly Results |
| 2025-08-04 | Quarterly Results & Interim Dividend |
| 2025-05-26 | Audited Results |
| 2025-02-06 | Quarterly Results |
| 2024-11-09 | Quarterly Results |
| 2024-08-10 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-11-11 | 2026-11-11 | View More |
| Buyback Period | ||
|---|---|---|
| 3 Nov - 09 Nov 26 12.30 pm | View More |
Aurobindo Pharma News
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Restructuring
Aurobindo Pharma announced the Scheme of Amalgamation for the merger of its wholly-owned subsidiaries Auroactive Pharma and Apitoria Pharma. The consolidation aims to streamline the API business and optimize capacity utilization with no change in the listed entity's shareholding.
Nov 04 2026 20:28:24
Aurobindo Pharma Ltd - 524804 - Intimation Of Record Date For Payment Of Interim Dividend For FY 2026-2027.
Aurobindo Pharma has declared an interim dividend of ₹7 per equity share for FY27. The company fixed November 11 2026 as the record date, with the payout scheduled on or before November 20 2026.
Nov 04 2026 20:20:32
Aurobindo Pharma Ltd - 524804 - Corporate Action-Board approves Dividend
Aurobindo Pharma announced an interim dividend of ₹7.00 per share for FY 2026-27. The record date is set for November 11, 2026, and the payout will be completed on or before November 20, 2026.
Nov 04 2026 20:16:01
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aurobindo Pharma reported Q2 FY27 results with cons. revenue of Rs.10,263 crore, a 24% YoY increase. Net profit rose 32.5% YoY to Rs.1,124 crore, driven by US and Europe sales, alongside an interim dividend declaration of Rs.7 per share.
Nov 04 2026 20:03:15
Aurobindo Pharma Ltd - 524804 - Board Meeting Outcome for Outcome Of Board Meeting
Aurobindo Pharma reported Q2 FY27 cons. revenue of ₹10,227.28 crores (up 24.1% YoY) and net profit of ₹1,126.08 crores (up 32.7% YoY). The Board declared an interim dividend of ₹7 per share with a record date of November 11, 2026, and approved the amalgamation of its wholly-owned subsidiaries.
Nov 04 2026 19:59:48
Aurobindo Pharma Ltd - 524804 - Board Meeting Intimation for Intimation Of Board Meeting
Aurobindo Pharma's board will meet on 4 November 2026. The agenda includes financial results and consideration of an interim dividend for FY 2026-27.
Oct 26 2026 07:48:35
Aurobindo Pharma Management
| Name | Position |
|---|---|
| Mangalam Ramasubramanian Kumar | Chairman |
| K Nityananda Reddy | Vice Chairman & Managing Director |
Aurobindo Pharma Similar Stocks
Lenskart Solutions Ltd.
724.75
6.40 (0.89%)
Zydus Lifesciences Ltd.
1197.90
4.90 (0.41%)
Dr. Reddy's Laboratories Ltd.
1373.00
7.00 (0.51%)
Cipla Ltd.
1411.00
6.90 (0.49%)
Mankind Pharma Ltd.
2540.00
22.00 (0.87%)
Lupin Ltd.
1988.10
0.10 (0.01%)
Max Healthcare Institute Ltd.
934.00
2.00 (0.21%)
Manipal Health Enterprises Ltd.
646.70
-10.55 (1.61%)
Glenmark Pharmaceuticals Ltd.
2590.00
108.20 (4.36%)
Aster DM Quality Care Ltd.
713.15
-6.40 (0.89%)
Aurobindo Pharma FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in AUROPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC
Or Download Choice FinX App
Invest in AUROPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade